ShRNA kinome screen identifies TBK1 as a therapeutic target for HER2 + breast cancer

Cancer Research

Volumn 74, Issue 7, 2014, Pages 2119-2130

  Deng, Tao ^a   Liu, Jeff C ^a   Chung, Philip E D ^a   Uehling, David ^b   Aman, Ahmed ^b   Joseph, Babu ^b   Ketela, Troy ^c   Jiang, Zhe ^a   Schachter, Nathan F ^d   Rottapel, Robert ^e   Egan, Sean E ^d   Al Awar, Rima ^b,f   Moffat, Jason ^c   Zacksenhaus, Eldad ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Drug Discovery Program Department of Pharmacology and Toxicology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ATG1; PROTEIN P160; PROTEIN P53; PROTEIN ULK1; SHORT HAIRPIN RNA; SYNAPTOTAGMIN I; TANK BINDING KINASE 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER SCREENING; CELL CYCLE ARREST; CELL IMMORTALIZATION; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR LIBRARY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SENSITIVITY ANALYSIS; TUMOR CELL; TUMOR INITIATING CELL;

ANIMALS; APOPTOSIS; AUTOPHAGY; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; FEMALE; GENES, P53; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, SCID; MUTATION; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA;

EID: 84897410164     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2138     Document Type: Article

References (50)

1. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2010;15:39-48.
2. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
3. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
4. Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 2011;17:952-8.
5. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008;44:2806-12.
6. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12: 236-44.
7. Dick JE. Breast cancer stem cells revealed. Proc Natl Acad Sci U S A 2003;100:3547-9.
8. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-96.
9. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere-And tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res 2007;67:8671-81.
10. Diamandis P, Wildenhain J, Clarke ID, Sacher AG, Graham J, Bellows DS, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol 2007;3:268-73.
11. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85.
12. Bao S,WuQ, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
13. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
14. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
15. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of neu protooncogene in the mammary epithelium of transgenic mouse induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578-82.
16. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389-97.
17. Dillon RL, Muller WJ. Distinct biological roles for the akt family in mammary tumor progression. Cancer Res 2010;70:4260-4.
18. Kurpios NA, Girgis-Gabardo A, Hallett RM, Rogers S, Gludish DW, Kockeritz L, et al. Single unpurified breast tumor-initiating cells from multiple mouse models efficiently elicit tumors in immune-competent hosts. PLoS ONE 2013;8:e58151.
19. Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, et al. Seventeen-gene signature from enriched Her2/Neu mammary tumorinitiating cells predicts clinical outcome for human HER2+:ERalphabreast cancer. Proc Natl Acad Sci U S A 2012;109:5832-7.
20. Deng T, Liu JC, Pritchard KI, Eisen A, Zacksenhaus E. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine/tesmilifene. Clin Cancer Res 2009;15: 119-30.
21. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
22. Wiederschain D, Wee S, Chen L, Loo A, Yang G, Huang A, et al. Singlevector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 2009;8:498-504.
23. Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basallike/ EMT tumor subtypes depending on p53 status. J Clin Invest 2010;120:3296-309.
24. Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS. neu/ ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 1997;17:3155-63.
25. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
26. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
27. Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011;30:631-41.
28. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
29. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
30. Ciavarra G, Zacksenhaus E. Rescue of myogenic defects in Rbdeficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift. J Cell Biol 2010;191:291-301.
31. Klionsky DJ,Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445-544.
32. Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, et al. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factorkappaB activation in breast cancer cells. Cancer Res 2005;65: 11375-83.
33. Adli M, Baldwin AS. IKK-i/IKKepsilon controls constitutive, cancer cellassociated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006;281:26976-84.
34. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-79.
35. Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 2009;284:14136-46.
36. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011;41:458-70.
37. Amir E, Ocana A, Seruga B, Freedman O, Clemons M. Lapatinib and HER2 status: results of a meta-Analysis of randomized phase III trials in metastatic breast cancer. Cancer Treat Rev 2010;36:410-5.
38. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006;11:857-67.
39. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100:1092-103.
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
41. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS ONE 2011;5:e13984.
42. Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A 2011;108:6474-9.
43. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132:344-62.
44. Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, et al. Control of the senescence-Associated secretory phenotype by NFTBK1 kappaB promotes senescence and enhances chemosensitivity. Genes Dev 2011;25:2125-36.
45. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW.Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
46. Livesey KM, Tang D, Zeh HJ, Lotze MT. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs 2009;10:1269-79.
47. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov 2012;2:172-89.
48. Cao Y, Luo JL, Karin M. IkappaBkinase alpha kinase activity is required for self-renewal of ErbB2/Her2-Transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A 2007;104:15852-7.
49. Zhang W, Tan W, Wu X, Poustovoitov M, Strasner A, Li W, et al. A NIKIKKalpha module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell 2013;23:647-59.
50. Newman AC, Scholefield CL, Kemp AJ, Newman M, McIver EG, Kamal A, et al. TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-kappaB signalling. PLoS ONE 2012;7:e50672.